Nektar Therapeutics Liabilities 2024

Nektar Therapeutics Aktienanalyse

What does Nektar Therapeutics do?

"Answer: Nektar Therapeutics is an American biopharmaceutical company based in San Francisco, specializing in the discovery and development of drugs for the treatment of cancer, autoimmune, and chronic metabolic diseases. The company was founded in 1990 by CEO Howard Robin and his team, initially focused on researching new technologies for drug development and later shifted to developing drugs for cancer therapy. Nektar Therapeutics has a unique business model that involves partnering with major pharmaceutical companies and other partners to develop a wide range of products, which are then licensed to these partners for commercialization and distribution. The company operates in several sectors, including oncology, pain management, autoimmune diseases, and metabolic diseases. Its important products include Movantik for opioid-induced constipation and ONZEALD for pancreatic cancer treatment. Nektar Therapeutics has made significant progress in developing immunoncology drugs, with potential projects such as NKTR-214 for advanced skin cancers. With its leading position in innovative drug development and strategic partnerships, the company has the potential to become a major player in cancer therapy." Nektar Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing Nektar Therapeutics's Liabilities

Nektar Therapeutics's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Nektar Therapeutics's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Nektar Therapeutics's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Nektar Therapeutics's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Nektar Therapeutics’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Nektar Therapeutics Stock

What is the level of liabilities of Nektar Therapeutics this year?

Nektar Therapeutics has a debt balance of 267.05 M USD this year.

What were the liabilities of Nektar Therapeutics compared to the previous year?

The liabilities of Nektar Therapeutics have increased by -22.37% dropped compared to the previous year.

What are the consequences of high debt for investors of Nektar Therapeutics?

High liabilities can pose a risk for investors of Nektar Therapeutics, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in Nektar Therapeutics?

Low liabilities mean that Nektar Therapeutics has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of Nektar Therapeutics affect the company?

An increase in liabilities of Nektar Therapeutics can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of Nektar Therapeutics affect the company?

A decrease in the liabilities of Nektar Therapeutics can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of Nektar Therapeutics?

Some factors that can influence the liabilities of Nektar Therapeutics include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of Nektar Therapeutics so important for investors?

The liabilities of Nektar Therapeutics are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can Nektar Therapeutics take to modify the liabilities?

To change its liabilities, Nektar Therapeutics can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does Nektar Therapeutics pay?

Over the past 12 months, Nektar Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Nektar Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Nektar Therapeutics?

The current dividend yield of Nektar Therapeutics is .

When does Nektar Therapeutics pay dividends?

Nektar Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Nektar Therapeutics?

Nektar Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Nektar Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Nektar Therapeutics located?

Nektar Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Nektar Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Nektar Therapeutics from 6/16/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/16/2024.

When did Nektar Therapeutics pay the last dividend?

The last dividend was paid out on 6/16/2024.

What was the dividend of Nektar Therapeutics in the year 2023?

In the year 2023, Nektar Therapeutics distributed 0 USD as dividends.

In which currency does Nektar Therapeutics pay out the dividend?

The dividends of Nektar Therapeutics are distributed in USD.